EBS Emergent Biosolutions Inc.

61.34
+3.68  (+6%)
Previous Close 57.66
Open 60
Price To Book 2.93
Market Cap 3,171,278,000
Shares 51,700,000
Volume 457,079
Short Ratio 3.9
Av. Daily Volume 494,883
Stock charts supplied by TradingView

NewsSee all news

  1. Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19

    BARDA to provide $14.5 million in funding to support development of COVID-Human Immune Globulin (COVID-HIG), a human plasma-derived therapy candidate being developed as a potential treatment for COVID-19 in severe

  2. Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

    CDMO agreement for NanoFlu to support pathway to licensureExpanded collaboration now includes NanoFlu and COVID-19 vaccine candidate GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

  3. VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE

    SOUTH SAN FRANCISCO, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection,

  4. EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE

    GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company,

  5. Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease

    Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) being developed as a potential treatment for severe hospitalized patients and protection for at-risk individualsEquine-derived polyclonal hyperimmune

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to commence in 2020.
FLU-IGIV
Influenza A
Approved May 17, 2012.
BioThrax
Anthrax Vaccine
Approved November 24, 2015.
BioThrax
Anthrax Vaccine Adsorbed
Approved March 25, 2015.
Anthrax Immune Globulin Intravenous (Human) [AIGIV]
Anthrax
Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.
VLA1601
Zika vaccine
Phase 2 interim analysis noted 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) within seven days after vaccination - November 22, 2019.
CHIKV-VLP
Chikungunya virus
Phase 1 trial to be initiated early 2H 2020.
cGMP vaccine
Coronavirus COVID-19 Vaccine

Latest News

  1. Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19

    BARDA to provide $14.5 million in funding to support development of COVID-Human Immune Globulin (COVID-HIG), a human plasma-derived therapy candidate being developed as a potential treatment for COVID-19 in severe

  2. Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

    CDMO agreement for NanoFlu to support pathway to licensureExpanded collaboration now includes NanoFlu and COVID-19 vaccine candidate GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

  3. VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE

    SOUTH SAN FRANCISCO, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection,

  4. EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE

    GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company,

  5. Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease

    Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) being developed as a potential treatment for severe hospitalized patients and protection for at-risk individualsEquine-derived polyclonal hyperimmune

  6. Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease

    GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will collaborate with

  7. Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite

    TORONTO, March 04, 2020 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions (NYSE:EBS), a

  8. Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019

    GAITHERSBURG, Md., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and year ended December 31, 2019. FINANCIAL HIGHLIGHTS (in millions)Q4

  9. Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020

    GAITHERSBURG, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the

  10. Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency

    GAITHERSBURG, Md., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a

  11. Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate

    GAITHERSBURG, Md., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for

  12. Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast

    Full year 2019 preliminary revenues and adjusted profitability metrics in line with prior guidanceFull year 2020 forecast reflects continued growth of core business as well as investments in key development programs and

  13. Emergent BioSolutions to Participate in Investor Conferences

    GAITHERSBURG, Md., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's executive management team will participate in the following investor conferences

  14. Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors

    GAITHERSBURG, Md., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have been recognized as

  15. Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate

    GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of

  16. Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day

    GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the

  17. Emergent BioSolutions to Host 2019 Analyst and Investor Day

    GAITHERSBURG, Md., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in New York City. This event

  18. Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019

    Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the third

  19. Emergent BioSolutions to Host 2019 Analyst & Investor Day

    GAITHERSBURG, Md., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New York City. This event, which

  20. Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

    GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company's chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was

  21. Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019

    GAITHERSBURG, Md., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the

  22. Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

    GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National

  23. Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

    GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's senior management team will participate in the Cantor Fitzgerald Global

  24. Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense

    GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing

  25. Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile

    Reaffirms ACAM2000 as a key component of the U.S. preparedness stance against the threat of smallpox as a biologic weaponSupports the government's continued efforts and long-term strategy to maintain sufficient